Amphista Therapeutics nabs $53m Series B
Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing.
Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination